ClinicalTrials.gg
RecruitingNCT03736889Updated Oct 26, 2026

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

A Phase 2 interventional study of Tislelizumab (BGB-A317) in MSI-H/dMMR Solid Tumors, sponsored by BeiGene. Recruiting at 29 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2018; still recruiting 8 years 1 month later.
Updated Oct 26, 2026Site recruiting status changed1 site removedGo to Updates ↓
Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317).

02

Conditions studied

  • MSI-H/dMMR Solid Tumors

Keywords

  • MSI-H/dMMR
  • Solid tumors
  • PD-1
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Having histological confirmed diagnosis of
  2. Having locally advanced unresectable or solid tumors with MSI-H or dMMR
  3. Having received prior cancer therapy regimen(s) for advanced disease.
  4. At least 1 as defined per Version (v) 1.1
  5. (ECOG) Performance Status ≤ 1
  6. Adequate organ function

Key Exclusion Criteria:

  1. Prior therapy with an , anti-PD-L1, anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  2. Active or uncontrolled .
  3. pleural effusion, pericardial effusion or ascites
  4. Active diseases or history of autoimmune diseases that may relapse
  5. Any active malignancy
  6. Any condition that required systemic treatment with either (> 10 mg daily of prednisone or equivalent) or other medication ≤ 14 days before the first dose of study drug
  7. Having a history of interstitial lung disease, non-infectious pneumonitis, pulmonary fibrosis, acute lung diseases, or uncontrolled systemic diseases (including but not limited to diabetes, hypertension, etc.)
  8. Participants with uncontrolled diabetes or uncontrolled electrolyte disorders despite standard medical management
  9. Having severe chronic or active infections
  10. A known history of infection
  11. Child - Pugh B or greater cirrhosis
  12. Any major surgical procedure ≤ 28 days before the first dose of study drug
  13. Prior stem cell transplantation or organ transplantation

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Tislelizumab (BGB-A317) Injection

    Drug: Tislelizumab (BGB-A317)

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate assessed by Independent Review Committee per Response Evaluation Criteria in Solid Tumors Version 1.1

    Time frame: Up to 2 years

Secondary outcomes

  1. Duration of response assessed by Independent Review Committee and by investigator per Response Evaluation Criteria in Solid Tumors Version 1.1

    Time frame: Up to 2 years

  2. Time to response assessed by Independent Review Committee and by investigator per Response Evaluation Criteria in Solid Tumors Version 1.1

    Time frame: Up to 2 years

  3. Progression-free survival assessed by Independent Review Committee and by investigator per Response Evaluation Criteria in Solid Tumors Version 1.1

    Time frame: Up to 2 years

  4. Disease control rate assessed by Independent Review Committee and by investigator per Response Evaluation Criteria in Solid Tumors Version 1.1

    Time frame: Up to 2 years

  5. Overall survival

    Time frame: Up to 2 years

  6. Objective response rate assessed by investigator per Response Evaluation Criteria in Solid Tumors Version 1.1

    Time frame: Up to 2 years

  7. Safety and tolerability assessment per the number of participants experiencing Treatment-Emergent Adverse Event (TEAE) as assessed by CTCAE v5.0

    Time frame: Up to 2 years

07

Study locations

6 of 29 sites recruiting
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
    Completed

    Not enrolling at this site — choose another above.

  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100021, China
    Completed

    Not enrolling at this site — choose another above.

  • The Affiliated Hospital of Military Medical Sciences
    Beijing, Beijing Municipality 100071, China
    Completed

    Not enrolling at this site — choose another above.

  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
    Recruiting
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing Municipality 400030, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
    Recruiting
  • Guangdong Provincial Peoples Hospital
    Guangzhou, Guangdong 510080, China
    Completed

    Not enrolling at this site — choose another above.

  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
    Completed

    Not enrolling at this site — choose another above.

  • The Sixth Affiliated Hospital, Sun Yat Sen University
    Guangzhou, Guangdong 510655, China
    Completed

    Not enrolling at this site — choose another above.

  • Huizhou First Hospital
    Huizhou, Guangdong 516000, China
    Recruiting
  • Meizhou People Hospital
    Meizhou, Guangdong 514031, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The Peoples Hospital of Hechi
    Hechi, Guangxi 547099, China
    Recruiting
  • Affiliated Hospital of Hebei University
    Baoding, Hebei 071000, China
    Completed

    Not enrolling at this site — choose another above.

  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
    Recruiting
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
    Completed

    Not enrolling at this site — choose another above.

  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
    Completed

    Not enrolling at this site — choose another above.

  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
    Completed

    Not enrolling at this site — choose another above.

  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
    Completed

    Not enrolling at this site — choose another above.

  • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210008, China
    Completed

    Not enrolling at this site — choose another above.

  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
    Completed

    Not enrolling at this site — choose another above.

  • Jilin Cancer Hospital
    Changchun, Jilin 130021, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The General Hospital of Shenyang Military
    Shenyang, Liaoning 110016, China
    Completed

    Not enrolling at this site — choose another above.

  • Yidu Central Hospital of Weifang
    Weifang, Shandong 262550, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200000, China
    Completed

    Not enrolling at this site — choose another above.

  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai Municipality 200032, China
    Completed

    Not enrolling at this site — choose another above.

  • The First Peoples Hospital of Yibin
    Yibin, Sichuan 644000, China
    Recruiting
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
    Completed

    Not enrolling at this site — choose another above.

  • Zhejiang University College of Medicine Second Affiliated Hospital
    Hangzhou, Zhejiang 310009, China
    Completed

    Not enrolling at this site — choose another above.

  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
    Completed

    Not enrolling at this site — choose another above.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2018 (actual). Primary completion is estimated for Nov 2026, 98 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2018
First posted
Nov 9, 2018
StartActual
Sep 19, 2018
Primary completionEst.
Nov 2026
CompletionEst.
Sep 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed. 7 sites changed recruiting status (4 now active, not recruiting, 3 now recruiting)
Show 7 sites
  • Chongqing University Cancer Hospital · Chongqing, ChinaRecruiting→Active, not recruiting
  • Fujian Medical University Union Hospital · Fuzhou, ChinaActive, not recruiting→Recruiting
  • Meizhou People Hospital · Meizhou, ChinaRecruiting→Active, not recruiting
  • The Peoples Hospital of Hechi · Hechi, ChinaActive, not recruiting→Recruiting
  • Jilin Cancer Hospital · Changchun, ChinaCompleted→Active, not recruiting
  • Yidu Central Hospital of Weifang · Weifang, ChinaCompleted→Active, not recruiting
  • The First Peoples Hospital of Yibin · Yibin, ChinaActive, not recruiting→Recruiting
Show 1 removed
  • Beijing Cancer Hospital · Beijing, China
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    1 site removed. 7 sites changed recruiting status (4 now active, not recruiting, 3 now recruiting)
    Show 7 sites
    • Chongqing University Cancer Hospital · Chongqing, ChinaRecruiting→Active, not recruiting
    • Fujian Medical University Union Hospital · Fuzhou, ChinaActive, not recruiting→Recruiting
    • Meizhou People Hospital · Meizhou, ChinaRecruiting→Active, not recruiting
    • The Peoples Hospital of Hechi · Hechi, ChinaActive, not recruiting→Recruiting
    • Jilin Cancer Hospital · Changchun, ChinaCompleted→Active, not recruiting
    • Yidu Central Hospital of Weifang · Weifang, ChinaCompleted→Active, not recruiting
    • The First Peoples Hospital of Yibin · Yibin, ChinaActive, not recruiting→Recruiting
    Show 1 removed
    • Beijing Cancer Hospital · Beijing, China

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03736889
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Nov 9, 2018
Start date
Sep 19, 2018
Primary completion
Nov 2026 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

BeiGene
Contact
clinicaltrials@beigene.com
+1-877-828-5568
Lin Shen, PhD
principal investigator · Peking University Cancer Hospital & Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion